Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 49-59

  Welliver, Mark ^a,c   McDonough, John ^a,c   Kalynych, Nicholas ^a,b,c   Redfern, Robert ^c  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Encapsulation; Modified cyclodextrin; Muscle relaxants; Neuromuscular blockade reversal; Selective relaxant binding agent (SRBA); Sugammadex

Indexed keywords

AMINOPHYLLINE; ATRACURIUM; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTISONE; CYCLODEXTRIN; DIGOXIN; EDROPHONIUM; EPHEDRINE; FENTANYL; GENTAMICIN; GLYCOPYRRONIUM BROMIDE; HYDROCORTISONE; NEOSTIGMINE; PANCURONIUM; PHENTOLAMINE; PROPOFOL; REMIFENTANIL; ROCURONIUM; SALBUTAMOL; SEVOFLURANE; SUGAMMADEX; VANCOMYCIN; VECURONIUM; VERAPAMIL;

ABDOMINAL DISCOMFORT; ALLERGIC REACTION; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENCAPSULATION; ERYTHEMA; FEVER; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; MYDRIASIS; NAUSEA; NEUROMUSCULAR BLOCKING; NONHUMAN; PARALYSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SMELLING AND TASTE; TACHYCARDIA; URINE RETENTION; VOMITING; X RAY CRYSTALLOGRAPHY; XEROSTOMIA;

EID: 67651154018     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s2757     Document Type: Review

References (70)

1. Adam JM, Bennett DJ, Bom A, et al. 2002. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem, 45:1806-1816 (Pubitemid 34415376)
2. Alvarez-Gomez JA, Wattwil M, Vanacker B, et al. 2007. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur J Anaesthesiol, 24(Suppl 39):124-125
3. Amao R, Zornow MH, Cowan MR, et al. 2007. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology, 107:A1582.
4. Appelboam R, Mulder R, Saddler J. 2003. Atracurium associated with post operative residual curarization. Correspondence. Br J Anaesthesiol, 90:523-528 (Pubitemid 36432450)
5. Baillard C, Gehan G, Reboul-Marty J, et al. 2000. Residual curarization in the recovery room after vecuronium. Br J of Anaesthesiol, 84:394-395 (Pubitemid 30114138)
6. Berg H, Roed J, Viby-Mogenson J, et al. 1997. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium, and pancuronium. Acta Anaesthesiol Scand, 41:1095-1103
7. Blobner M, Eriksson L, Scholz J, et al. 2007. Sugammadex 92.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 mcg/kg). Eur J Anaesthsiol, 24(Suppl 39):125.
8. Bohm R. 1912. Ueber die Verbindung der Lokalanasthesie mit der Narkose, uber hohe Extraduralanasthesie und epidurale Injektion anastesierender Losenungen bei tabischen Magenkrisen. Beitrage zur Klinischen Chirurgie. 80:168-189
9. Bom A, Bradley M, Cameron K, et al. 2002a. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Agnew Chem Int Ed, 41:266-270 (Pubitemid 34126377)
10. Bom A, Clark JK, Palin R. 2002b. New approaches to reversal of neuromuscular block. Curr Opin Drug Discov Develop, 5:793-800. (Pubitemid 36253799)
11. Bom A, Epemolu O, Hope F, et al. 2007. Selective relaxant binding agent for reversal of neuromuscular blockade. Curr Opin Pharmacol, 7:298-302. (Pubitemid 46731191)
12. Bom A, Hope F. 2007. Propanolol and isprenaline do not modify the sugammadex-induced fast recovery from neuromuscular blockade. Eur J Anaesthesiol, 24:111-112
13. Bom A, Mason R, McIndewar I. 2002c. Org 25969 causes rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base status. Anesthesiology, 96:A-1009.
14. Bom A, Van Egmond J, Hope F, et al. 2003. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion. Anesthesiology, 99:A-1158.
15. Challa R, Ahula A, Ali J, et al. 2005. Cyclodextrins in drug delivery: an updated review. AAPS Pharma Sci Tech, 6:329-357 (Pubitemid 41631739)
16. Debaene B, Plaud B, Dilly MP, et al. 2003. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology, 98:1042-1048 (Pubitemid 36520189)
17. Dahl V, Pendeville PE, Hollman MW, et al. 2007. Reversal of rocuronium-induced blockade by sugammadex in cardiac patients. Anesthesiology, 107:A1581.
18. de Boer H, Driessen J, Marcus M, et al. 2007. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-. nding and safety study. Anesthesiology, 107:239-244 (Pubitemid 47196486)
19. de Boer HD, van Egmond J, van de Pol F, et al. 2006. Reversal of profound neuromuscular blockade by sugammadex in anesthesized rhesus monkeys. Anesthesiology, 104:718-723
20. Decoopman M, Cammu G, Suy K, et al. 2007. Reversal of pancuronium-induced block by the selective relaxany binding agent sugammadex. Eur J Anaesthesiol, 24(Suppl 39):110-111
21. de Kam P-J, van Kuijk J, Smeets J, et al. 2007. Single IV sugammaedx doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology, 107:A1580.
22. Duvaldestin P, Kuizenga K, Kjaer CC, et al. 2007. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose-response study. Eur J Anaesthesiol, 24(Suppl 39):123.
23. Eikerman M, Blobner M, Groeben H, et al. 2006. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg, 102:937-942 (Pubitemid 43306424)
24. Eleveld DJ, Kuizenga K, Proost JH, et al. 2007. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg, 104:582-584 (Pubitemid 46309876)
25. Epemolu O, Bom A, Hope F, et al. 2003. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology, 99:632-637 (Pubitemid 37051978)
26. Eriksson LI. 1999. The effects of residual neuromuscular blockade and volatile anesthestics on the control of ventilation. Anesth Analg, 89:243-251
27. Flockton E, Scanni E, Gomar C, et al. 2007. Sugammadex after rocuronium provides faster recovery from neuromuscular blockade than neostigmine after cisatracurium. Eur J Anaesthesiol, 24(Suppl 39):123.
28. Gijsenbergh F, Ramael S, Houwing N, et al. 2005. First human exposure of Org 25969. A novel agent to reverse the action of rocuronium bromide. Anesthesiology, 103:695-703. (Pubitemid 41415517)
29. Glycopyrrolate injection package insert. 2002. American Regent Laboratories, Inc. Sept. 2002. Shirley NY. USA.
30. Griffith HR, Johnson GE. 1942. The use of curare in general anesthesia. Anesthesiology, 3:418.
31. Harris AM, Welliver M, Redfern R, et al. 2007. Orthopaedic surgery implications of a novel encapsulation process that improves neuromuscular blockade and reversal. The Internet Journal of Orthopedic Surgery, 7(2).
32. Hartmann J, Smeets JMW, deZwart MAH, et al. 2007. In-vitro dialysability of sugammadex, a selective relaxant binding agent for reversal of neuromuscular block induced by rocuronium. Accessed March 10, 2007.Available at: www.euroanesthesia.org/abstractresults/Madrid2006/f-h.php.
33. Hayes AH, Mirakhur RK, Breslin DS, et al. 2001. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anesthesia, 56:312-318
34. Jones RK, Caldwell JE, Brull SJ, et al. 2007. Faster reversal of profound rocuronium-induced neuromuscular blockade with sugammadex vs neostigmine. Anesthesiology, 107:A1577.
35. Khunl-Brady K, Rex C, Sielenkamper A, et al. 2005. Reversal of high-dose rocuronium with Org 25969. Eur J Anaesthesiol, 22(Suppl 34):121.
36. Kirkegaard H, Heier T, Caldwell J. 2002. Ef. cacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology, 96:45-50. (Pubitemid 34032480)
37. Kopman AF. 2006. Sugammadex: A revolutionary approach to neuromuscular antagonism. Anesthesiology, 104:631-633
38. Lemmens HJM, El-Orbany MI, Berry J, et al. 2007. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology, 107:A1578.
39. Loftsson T, Pekka J, Mar M, et al. 2005. Cyclodextrins in drug delivery. Expert Opin Drug Deliv, 2:1-17.
40. Liu L, Guo Q-X. 2002. The driving forces in the inclusion complexation of cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 42:1-14. (Pubitemid 38075810)
41. MacPherson RD. 2001. Pharmaceuticals for the anaesthetist. Anaesthesia, 56:965-979
42. Mason R, Bom A. 2001. Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBs in anesthetized guinea pigs. Eur J Anaesthesiol, 18(Suppl 23):100.
43. McDonagh DL, Benedict PE, Kovac AL, et al. 2007. Efficacy and safety for reversal of rocuronium-induced blockade in elederly patients. Anesthesiology, 107:A1583.
44. Molina AL, de Boer HD, Klimekl M, et al. 2007. Reversal of rocuronium-induced (1.2 mg kg-1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg-1). Br J Anaesth, 98:624-627
45. Murphy GS. 2006. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anesthesiol, 72:97-109.
46. Murphy GS, Szokol JW, Marymont JH, et al. 2005. Residual paralysis at the time of tracheal extubation. Anesth Analg, 100:1840-1845.
47. Naguib M. 2007. Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg, 104:575-581 (Pubitemid 46331731)
48. Neostigmine package insert. 2002. American Regent Laboratories, Inc. Sept. 2002. Shirley NY. USA.
49. Plaud B, Meretoja O, Pohl B, et al. 2007. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients. Eur J Anaesthesiol, 24(Suppl 39):124.
50. Puhringer F, Blaszyk M, Cammu G, et al. 2007. Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium of vecuronium: dose-response studies. Eur J Anaesthesiol, 24 (Suppl 39):111.
51. Rex C, Khuenl-Brady K, Sielenkaemper, et al. 2005. Reversal of high-dose rocuronium (1.2 mg/kg) with Org 25969. Anesthesiology, A1129.
52. Rocuronium Bromide package insert. 2007. Organon International. Oss Netherlands. Accessed Oct 9, 2007. URL: http://www.zemuron.com/hcp/ productsummary/chemistry/index.asp?C=86765393246433 101852&svarqvp2=0.
53. Sacan O, White PF, Tufanogullari B, et al. 2007. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg, 104:569-574 (Pubitemid 46309875)
54. Shah RR. 2005. Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead. Drug Saf, 28:1009-1028
55. Shields M, Giovannelli M, Mirakhur RK, et al. 2006. Org 25069 (sugammadex) a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular blockade. Br J Anaesthesiol, 96:36-43. (Pubitemid 43124528)
56. Singh PD, Kaur J, Sidhu GS. 1982. Assessment of post-operative residual paralysis with muscle relaxants. Indian Journal of Anaesthesia, 30:483-488
57. Staals LM, Snoek MMJ, Flockton E, et al. 2007. The efficacy of sugammadex in subjects with impaired renal function. Eur J Anaesthesiol, 24(Suppl 39):122-123
58. Sorgenfrei IF, Norrild K, Larsen PB, et al. 2006. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology, 104:667-674
59. Suy K, Morias K, Cammu G, et al. 2007. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology, 106:283-288 (Pubitemid 46185173)
60. Szente J, Szejtli J. 1999. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev, 36:17-28. (Pubitemid 29074474)
61. Szejtli Jozsef. 2004. Past, present, and future of cyclodextrin research. Pure Appl Chem, 76:1825-1845
62. Tarver GJ, Grove SJ, Buchanan K, et al. 2002. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem, 10:1819-1827 (Pubitemid 34286374)
63. Thompson DO, Chaubal MV. 2002. Cyclodextrins (CDS) excipients by definition, drug delivery systems by function (part I: injectable applications). Drug Delivery Technology. 2(7):34-38.
64. Tramer MR, Fuchs-Buder T. 1999. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesthesiol, 82:379-386 (Pubitemid 29112540)
65. United States Department of Health and Human Services. 2007. Guidance for Industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrythmic potential for non-antiarrythmic drugs. Oct. 2005. Accessed Sept 10, 2007. URL: http://www.fda.gov/cber/gdlns/iche14qtc.htm.
66. Vanacker B, Vermeyen K, Struys MRF, et al. 2005. Reversal by Org 25969 is not affected by sevo. urane when compared with propofol. Eur J Anaesthesiol, 22(Suppl 34):119.
67. Vanacker BF, Vermeyen KM, Struys MMRF, et al. 2007. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg, 104:563-568
68. Welliver M. 2006. New drug sugammadex. AANA J, 74:357-363
69. Welliver M. 2007. Update for nurse anesthetists. Part 3. Cyclodextrin introduction to anesthesia practice: form, function, and application. AANA J, 75:289-296
70. Zhang M-Q. 2003. Drug-specific cyclodextrins: The future of rapid neuromuscular block reversal? Drugs Future, 28: 347-354